JP6912667B2 - 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用 - Google Patents

新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用 Download PDF

Info

Publication number
JP6912667B2
JP6912667B2 JP2020526718A JP2020526718A JP6912667B2 JP 6912667 B2 JP6912667 B2 JP 6912667B2 JP 2020526718 A JP2020526718 A JP 2020526718A JP 2020526718 A JP2020526718 A JP 2020526718A JP 6912667 B2 JP6912667 B2 JP 6912667B2
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutical composition
mixture
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528933A (ja
JP2020528933A5 (enExample
Inventor
ノア シェラッハ，
ノア シェラッハ，
Original Assignee
ルトリス ファーマ エル ティー ディー．
ルトリス ファーマ エル ティー ディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルトリス ファーマ エル ティー ディー．, ルトリス ファーマ エル ティー ディー． filed Critical ルトリス ファーマ エル ティー ディー．
Publication of JP2020528933A publication Critical patent/JP2020528933A/ja
Publication of JP2020528933A5 publication Critical patent/JP2020528933A5/ja
Application granted granted Critical
Publication of JP6912667B2 publication Critical patent/JP6912667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2020526718A 2017-07-29 2018-07-26 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用 Active JP6912667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538675P 2017-07-29 2017-07-29
US62/538,675 2017-07-29
PCT/IL2018/050836 WO2019026065A2 (en) 2017-07-29 2018-07-26 NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Publications (3)

Publication Number Publication Date
JP2020528933A JP2020528933A (ja) 2020-10-01
JP2020528933A5 JP2020528933A5 (enExample) 2021-03-04
JP6912667B2 true JP6912667B2 (ja) 2021-08-04

Family

ID=65233550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526718A Active JP6912667B2 (ja) 2017-07-29 2018-07-26 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用

Country Status (15)

Country Link
US (3) US10927112B2 (enExample)
EP (1) EP3661515B1 (enExample)
JP (1) JP6912667B2 (enExample)
KR (1) KR102328351B1 (enExample)
CN (1) CN111132680B (enExample)
AU (1) AU2018311538B2 (enExample)
CA (1) CA3070542C (enExample)
DK (1) DK3661515T3 (enExample)
ES (1) ES2908602T3 (enExample)
HR (1) HRP20220609T1 (enExample)
IL (1) IL272312B (enExample)
MX (1) MX383386B (enExample)
SI (1) SI3661515T1 (enExample)
WO (1) WO2019026065A2 (enExample)
ZA (1) ZA202000354B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458139B2 (en) * 2017-08-08 2022-10-04 Memorial Sloan Kettering Cancer Center Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor
MX2021009535A (es) 2019-02-12 2022-10-10 Lutris Pharma Ltd Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
WO2022136912A1 (en) * 2020-12-24 2022-06-30 Lutris Pharma Ltd. Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
WO2023275620A2 (en) * 2021-07-02 2023-01-05 Lutris Pharma Ltd. Use of isoquinoline-1,5-diamines for wound healing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
TWI611053B (zh) 2012-02-27 2018-01-11 曾宇鳳 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
RU2015149937A (ru) * 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CN109069511A (zh) 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途

Also Published As

Publication number Publication date
JP2020528933A (ja) 2020-10-01
ES2908602T3 (es) 2022-05-03
BR112020001935A2 (pt) 2020-07-28
ZA202000354B (en) 2024-01-31
RU2020108782A3 (enExample) 2021-09-02
WO2019026065A2 (en) 2019-02-07
US20210070757A1 (en) 2021-03-11
EP3661515B1 (en) 2022-02-23
KR20200035990A (ko) 2020-04-06
CA3070542C (en) 2021-05-18
HRP20220609T1 (hr) 2022-06-24
KR102328351B1 (ko) 2021-11-19
CA3070542A1 (en) 2019-02-07
MX383386B (es) 2025-03-13
CN111132680B (zh) 2022-02-08
EP3661515A2 (en) 2020-06-10
CN111132680A (zh) 2020-05-08
EP3661515A4 (en) 2021-01-06
AU2018311538B2 (en) 2021-03-25
DK3661515T3 (da) 2022-04-19
SI3661515T1 (sl) 2022-06-30
AU2018311538A1 (en) 2020-02-13
RU2020108782A (ru) 2021-09-02
US20190389862A1 (en) 2019-12-26
IL272312B (en) 2021-06-30
US11339163B2 (en) 2022-05-24
US10927112B2 (en) 2021-02-23
IL272312A (en) 2020-03-31
WO2019026065A3 (en) 2019-08-01
US20220274988A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CA3189410A1 (en) Kat6 inhibitor methods and combinations for cancer treatment
WO2021238827A1 (zh) Egfr抑制剂、其制备方法及用途
US20220274988A1 (en) Braf inhibitors and use thereof for treatment of cutaneous reactions
KR20220041180A (ko) 중소수화 mk2 경로 억제제 및 이를 이용하는 방법
EA003604B1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ
KR20100087298A (ko) 피부 질환의 예방 및/또는 치료제
WO2021016333A1 (en) Aryl sulfonamides as small molecule stat3 inhibitors
KR20240112283A (ko) Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법
CA3228505A1 (en) Treatment of hair loss disorders with deuterated jak inhibitors
KR20240150493A (ko) 화합물 및 그 용도
WO2018005444A2 (en) Methods for treating cancer
AU2005266493B2 (en) Inhibitors of Hsp90
KR101009554B1 (ko) Ｐｄｅ７ 억제제로서 스피로시클릭 퀴나졸린 유도체
CN103664734B (zh) 杂环羟肟酸类化合物及其药用组合物和应用
RU2779185C2 (ru) Новые ингибиторы braf и их применение для лечения кожных реакций
BR112020001935B1 (pt) Novos inibidores de braf e uso destes para o tratamento de reações cutâneas
KR20230022976A (ko) 알케닐 피리미딘 화합물, 그의 제조방법 및 그의 적용
CA2969856A1 (en) Novel quinazolines as biogenic amine transport modulators
RU2797694C2 (ru) О-аминогетероарилалкинилсодержащее соединение, способ его получения и его применение
WO2026082160A1 (zh) Wee1蛋白降解剂及其应用
KR20040015135A (ko) 20-히드록시에이코사테트라엔산 생산 저해제
CN119285594A (zh) 7-氨基苯并吡喃酮或7-氨基喹啉酮类化合物及其应用
CN116041369A (zh) 嘧啶并环类衍生物、其制备方法及其在医药上的用途
CN109776373A (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210122

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210122

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210708

R150 Certificate of patent or registration of utility model

Ref document number: 6912667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250